(AUPH) Aurinia Pharmaceuticals - Overview
Stock: Immunosuppressant, B-Cell Inhibitor
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 47.3% |
| Relative Tail Risk | -16.4% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.45 |
| Alpha | 67.56 |
| Character TTM | |
|---|---|
| Beta | 0.679 |
| Beta Downside | 0.289 |
| Drawdowns 3y | |
|---|---|
| Max DD | 60.80% |
| CAGR/Max DD | 0.36 |
Description: AUPH Aurinia Pharmaceuticals January 15, 2026
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) is a Canadian-based biopharma focused on oral therapies for autoimmune diseases with high unmet need. Its flagship product, LUPKYNIS (voclosporin), is approved for adult patients with active lupus nephritis, and the pipeline includes AUR200, a dual BAFF/APRIL inhibitor targeting broader autoimmune indications. The company maintains a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd., which provides commercial and development support.
According to the company’s most recent quarterly filing (Q3 2024), Aurinia reported net product revenue of $23 million, a 12 % YoY increase driven primarily by LUPKYNIS sales in the United States, while total cash and cash equivalents stood at $210 million, giving it roughly 18 months of runway at current burn rates. The net loss for the quarter was $48 million, reflecting ongoing R&D spend on AUR200 and commercial expansion. These figures suggest the firm is still in a growth-phase financing profile, with cash sufficiency contingent on continued market uptake and successful pipeline milestones.
The lupus nephritis market is projected to grow at a CAGR of ~7 % through 2030, propelled by rising disease prevalence and limited therapeutic options. Moreover, the broader autoimmune sector benefits from favorable reimbursement trends and increasing patient awareness, but competition is intensifying from both biologics (e.g., belimumab) and emerging oral agents. AUR200’s dual-target mechanism could differentiate it if Phase 2 data confirm efficacy and safety, yet the pathway remains uncertain given historical attrition rates for novel immunomodulators (~70 % failure before Phase 3).
For a deeper quantitative assessment of Aurinia’s valuation dynamics, you may find ValueRay’s analyst toolkit useful as a next step in your research.
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income: 77.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.23 > 0.02 and ΔFCF/TA 17.57 > 1.0 |
| NWC/Revenue: 136.4% < 20% (prev 164.2%; Δ -27.82% < -1%) |
| CFO/TA 0.23 > 3% & CFO 120.1m > Net Income 77.8m |
| Net Debt (5.02m) to EBITDA (102.4m): 0.05 < 3 |
| Current Ratio: 5.76 > 1.5 & < 3 |
| Outstanding Shares: last quarter (136.0m) vs 12m ago -6.62% < -2% |
| Gross Margin: 88.81% > 18% (prev 0.87%; Δ 8794 % > 0.5%) |
| Asset Turnover: 49.37% > 50% (prev 40.11%; Δ 9.25% > 0%) |
| Interest Coverage Ratio: 18.73 > 6 (EBITDA TTM 102.4m / Interest Expense TTM 4.43m) |
Altman Z'' 1.89
| A: 0.69 (Total Current Assets 438.7m - Total Current Liabilities 76.2m) / Total Assets 527.5m |
| B: -1.63 (Retained Earnings -860.2m / Total Assets 527.5m) |
| C: 0.15 (EBIT TTM 83.0m / Avg Total Assets 538.4m) |
| D: 1.58 (Book Value of Equity 255.9m / Total Liabilities 161.8m) |
| Altman-Z'' Score: 1.89 = BBB |
Beneish M -3.36
| DSRI: 0.70 (Receivables 30.9m/36.5m, Revenue 265.8m/220.4m) |
| GMI: 0.98 (GM 88.81% / 87.25%) |
| AQI: 0.77 (AQ_t 0.01 / AQ_t-1 0.01) |
| SGI: 1.21 (Revenue 265.8m / 220.4m) |
| TATA: -0.08 (NI 77.8m - CFO 120.1m) / TA 527.5m) |
| Beneish M-Score: -3.36 (Cap -4..+1) = AA |
What is the price of AUPH shares?
Over the past week, the price has changed by -4.53%, over one month by -4.09%, over three months by -2.42% and over the past year by +82.31%.
Is AUPH a buy, sell or hold?
- StrongBuy: 3
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the AUPH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 16.7 | 14.7% |
| Analysts Target Price | 16.7 | 14.7% |
| ValueRay Target Price | 15.7 | 8.3% |
AUPH Fundamental Data Overview February 03, 2026
P/E Forward = 18.8679
P/S = 7.2069
P/B = 5.2805
Revenue TTM = 265.8m USD
EBIT TTM = 83.0m USD
EBITDA TTM = 102.4m USD
Long Term Debt = 78.2m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 17.4m USD (from shortTermDebt, last quarter)
Debt = 78.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 5.02m USD (from netDebt column, last quarter)
Enterprise Value = 1.64b USD (1.92b + Debt 78.2m - CCE 351.8m)
Interest Coverage Ratio = 18.73 (Ebit TTM 83.0m / Interest Expense TTM 4.43m)
EV/FCF = 13.70x (Enterprise Value 1.64b / FCF TTM 119.9m)
FCF Yield = 7.30% (FCF TTM 119.9m / Enterprise Value 1.64b)
FCF Margin = 45.10% (FCF TTM 119.9m / Revenue TTM 265.8m)
Net Margin = 29.28% (Net Income TTM 77.8m / Revenue TTM 265.8m)
Gross Margin = 88.81% ((Revenue TTM 265.8m - Cost of Revenue TTM 29.7m) / Revenue TTM)
Gross Margin QoQ = 88.42% (prev 89.84%)
Tobins Q-Ratio = 3.11 (Enterprise Value 1.64b / Total Assets 527.5m)
Interest Expense / Debt = 1.41% (Interest Expense 1.10m / Debt 78.2m)
Taxrate = 1.29% (411.0k / 32.0m)
NOPAT = 81.9m (EBIT 83.0m * (1 - 1.29%))
Current Ratio = 5.76 (Total Current Assets 438.7m / Total Current Liabilities 76.2m)
Debt / Equity = 0.21 (Debt 78.2m / totalStockholderEquity, last quarter 365.8m)
Debt / EBITDA = 0.05 (Net Debt 5.02m / EBITDA 102.4m)
Debt / FCF = 0.04 (Net Debt 5.02m / FCF TTM 119.9m)
Total Stockholder Equity = 357.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 14.46% (Net Income 77.8m / Total Assets 527.5m)
RoE = 21.79% (Net Income TTM 77.8m / Total Stockholder Equity 357.2m)
RoCE = 19.06% (EBIT 83.0m / Capital Employed (Equity 357.2m + L.T.Debt 78.2m))
RoIC = 22.93% (NOPAT 81.9m / Invested Capital 357.2m)
WACC = 8.14% (E(1.92b)/V(1.99b) * Re(8.42%) + D(78.2m)/V(1.99b) * Rd(1.41%) * (1-Tc(0.01)))
Discount Rate = 8.42% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -2.76%
[DCF Debug] Terminal Value 69.56% ; FCFF base≈83.2m ; Y1≈54.6m ; Y5≈24.9m
Fair Price DCF = 3.57 (EV 475.4m - Net Debt 5.02m = Equity 470.4m / Shares 131.8m; r=8.14% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: 85.54 | EPS CAGR: 127.4% | SUE: -3.24 | # QB: 0
Revenue Correlation: 87.96 | Revenue CAGR: 35.67% | SUE: 1.02 | # QB: 2
EPS next Quarter (2026-03-31): EPS=0.18 | Chg30d=-0.013 | Revisions Net=+0 | Analysts=2
EPS next Year (2026-12-31): EPS=0.93 | Chg30d=-0.010 | Revisions Net=+2 | Growth EPS=+18.3% | Growth Revenue=+16.6%